RPL13A

Large ribosomal subunit protein uL13 · P40429 · RPL13A on Sugi Atlas →

3,675 patent compounds predicted against RPL13A, 1,926 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL13A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors	PHASE2	RECRUITING
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer	PHASE1	COMPLETED
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia	PHASE1	COMPLETED
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)	nan	COMPLETED
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth	nan	COMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Longitudinal Study of the Porphyrias	nan	RECRUITING
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma	nan	WITHDRAWN
Effect of Diaphragm Stimulation During Surgery	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a RPL13A binder may also engage these)

Protein	Name	Similarity
Q5RA38	—	1.000	Q5RA38 →
P19253	—	1.000	P19253 →
Q4R8Z2	—	1.000	Q4R8Z2 →
G1TVS8	—	1.000	G1TVS8 →
P35427	—	1.000	P35427 →
Q3SZ90	—	0.998	Q3SZ90 →
Q91487	—	0.998	Q91487 →
Q9XSU0	—	0.997	Q9XSU0 →
Q962U0	—	0.991	Q962U0 →
O42991	—	0.991	O42991 →
P26785	—	0.991	P26785 →
Q9P720	—	0.990	Q9P720 →
Q9VNE9	—	0.988	Q9VNE9 →
O49885	—	0.988	O49885 →
Q9LRX8	—	0.988	Q9LRX8 →
Q8MUR4	—	0.988	Q8MUR4 →
Q27389	—	0.988	Q27389 →
Q553M7	—	0.987	Q553M7 →
P0DJ15	—	0.986	P0DJ15 →
O65055	—	0.986	O65055 →
P93099	—	0.986	P93099 →
Q9SVR0	—	0.985	Q9SVR0 →
Q5AB87	—	0.985	Q5AB87 →
P26784	—	0.984	P26784 →
Q9SFU1	—	0.983	Q9SFU1 →
Q9FKC0	—	0.982	Q9FKC0 →
O43004	—	0.982	O43004 →
P14148	—	0.981	P14148 →
O42848	—	0.981	O42848 →
Q5RAH8	—	0.978	Q5RAH8 →